Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab

Emicizumab (Hemlibra™) is approved for prophylaxis of hemophilia A (HA) patients. The HAVEN studies addressed bleeding reduction in emicizumab-treated patients, but real-world data on bleeding patterns during emicizumab therapy are lacking. We aimed to compare the occurrence of breakthrough bleeding...

Full description

Bibliographic Details
Main Authors: Sarina Levy-Mendelovich, Tami Brutman-Barazani, Ivan Budnik, Einat Avishai, Assaf A. Barg, Tamara Levy, Mudi Misgav, Tami Livnat, Gili Kenet
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Journal of Clinical Medicine
Subjects:
emicizumab
hemophilia
monitoring
hemarthrosis
bleeding
Online Access:https://www.mdpi.com/2077-0383/10/19/4303

Internet

https://www.mdpi.com/2077-0383/10/19/4303

Similar Items